<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758134</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2007-001</org_study_id>
    <secondary_id>2007-003709-29</secondary_id>
    <nct_id>NCT00758134</nct_id>
  </id_info>
  <brief_title>Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients</brief_title>
  <official_title>Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armando Santoro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study assessing efficacy of trastuzumab therapy in pretreated NSCLC&#xD;
      patients. Patients with locally advanced or metastatic NSCLC, HER2 FISH positive and/or with&#xD;
      HER2 gene mutation, pretreated with at least one previous chemotherapy line will be&#xD;
      considered eligible for the trial. After evaluation of inclusion and exclusion criteria, and&#xD;
      after signature of informed consensus form, all eligible patients will receive trastuzumab 6&#xD;
      mg/kg every 3 weeks (8 mg/kg loading dose) until disease progression, unacceptable toxicity&#xD;
      or patient refusal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient accrual&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>every two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression, overall survival, safety and assessment of biomarkers potentially implicated in trastuzumab sensitivity/resistance</measure>
    <time_frame>every two months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>NON-SMALL CELL LUNG CANCER</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab 6 mg/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab (Herceptin)</intervention_name>
    <description>Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Histologically confirmed diagnosis of NSCLC. Availability of tumor tissue for HER2&#xD;
             FISH analysis and/or HER2 gene mutation analysis is mandatory&#xD;
&#xD;
               -  Stage IIIB (with effusion) or stage IV or disease relapsed after surgery or&#xD;
                  radiotherapy and in any case not suitable for radiotherapy or surgery with&#xD;
                  curative intent&#xD;
&#xD;
               -  HER2 FISH positive defined as high polysomy or gene amplification, or presence of&#xD;
                  HER2 gene mutation in exon 20&#xD;
&#xD;
               -  At least one measurable lesion&#xD;
&#xD;
               -  Patients pretreated with at least one chemotherapy regimen. Previous therapy with&#xD;
                  erlotinib or other tyrosine kinase inhibitors is allowed.&#xD;
&#xD;
               -  Patients compliance to trial procedures&#xD;
&#xD;
               -  Age ≥ 18 years&#xD;
&#xD;
               -  Written informed consent&#xD;
&#xD;
               -  Adequate BM function (ANC ≥1.5x109/L, Platelets ≥100x109/L, HgB &gt;9 g/dl)&#xD;
&#xD;
               -  Adequate liver function (bilirubin &lt;G2, transaminases no more than 3xULN/&lt;5xULN&#xD;
                  in present of liver metastases).&#xD;
&#xD;
               -  Normal level of alkaline phosphatase and creatinine&#xD;
&#xD;
               -  If female: childbearing potential either terminated by surgery, radiation, or&#xD;
                  menopause, or attenuated by use of approved contraceptive method [intrauterine&#xD;
                  contraceptive device (IUD), birth control pills, or barrier device] during and&#xD;
                  for three months after trial.&#xD;
&#xD;
               -  ECOG performance status 0-1 and life expectancy of at least 3 months&#xD;
&#xD;
               -  Have recovered from the acute, reversible effects of prior surgery or&#xD;
                  radiotherapy. This means that at least 3 weeks should have elapsed since prior&#xD;
                  radiotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • HER2 FISH negative tumor and no evidence of HER2 gene mutation in exon 20&#xD;
&#xD;
               -  Concomitant radiotherapy&#xD;
&#xD;
               -  Untreated brain metastases or leptomeningeal disease involvement.&#xD;
&#xD;
               -  All disease sites previously included in radiotherapy fields. If all sites were&#xD;
                  included in radiotherapy fields patient is eligible only if there is evidence of&#xD;
                  progressive disease after completion of radiotherapy.&#xD;
&#xD;
               -  No measurable lesion&#xD;
&#xD;
               -  Left ventricular ejection fraction (FEV) &lt;50%&#xD;
&#xD;
               -  Diagnosis of any other malignancy during the last 5 years, except for in situ&#xD;
                  carcinoma of cervix uteri and squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Any previous HER2 blocking therapy. Previous therapy with anti EGFR agents is&#xD;
                  allowed&#xD;
&#xD;
               -  Pregnancy or lactating&#xD;
&#xD;
               -  Other serious illness or medical condition including: Congestive heart failure&#xD;
                  (NYHA class II, III, IV) or history of documented congestive heart failure,&#xD;
                  unstable angina pectoris, myocardial infarction in the last 12 months, poorly&#xD;
                  controlled hypertension (systolic &gt;180 mmHg or diastolic &gt;100 mmHg), clinically&#xD;
                  significant valvular heart disease, or high-risk uncontrolled arrhythmias.&#xD;
                  Patients with dyspnoea at rest due to malignant or other disease (e.g. pulmonary&#xD;
                  metastases with lymphangitis) or who require supportive oxygen therapy. Active&#xD;
                  serious uncontrolled infections. Poorly controlled diabetes mellitus&#xD;
&#xD;
               -  Treatment with any investigational drug within 30 days before the beginning of&#xD;
                  treatment with study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Armando Santoro, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

